Carcinoma  >>  Rencarex (girentuximab)  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Merck (MSD)
NCT00602862: Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250

Completed
N/A
26
Europe
Sorafenib, Bevacizumab, Avastin, Nexavar, cG250, Rencarex, 111Indium-bevacizumab, avastin, indium, 111Indium-cG250, rencarex
Radboud University Medical Center, Dutch Cancer Society
Clear Cell Renal Cell Carcinoma
04/12
06/12
NCT02411968: Follow up After Cryoablation of Small Renal Masses.

Completed
N/A
9
Europe
111In-Girentuximab DOTA SPECT
Radboud University Medical Center
Carcinoma, Renal Cell
09/18
09/18

Download Options